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The mononuclear phagocytic system (MPS), comprised of mono-
cytes, macrophages, and dendritic cells, is essential in tissue
homeostasis and in determining the balance of the immune
response through its role in antigen presentation. It has been
identiﬁed as a therapeutic target in infectious disease, cancer,
autoimmune disease and transplant rejection. Here, we review
the current understanding of the immunophenotype and function
of the MPS in normal human liver. Using well-deﬁned selection
criteria, a search of MEDLINE and EMBASE databases identiﬁed
76 appropriate studies. The majority (n = 67) described Kupffer
cells (KCs), although the deﬁnition of KC differs between sources,
and little data were available regarding their function. Only 10
papers looked at liver dendritic cells (DCs), and largely conﬁrmed
the presence of the major dendritic cell subsets identiﬁed in
human blood. Monocytes were thoroughly characterized in four
studies that utilized ﬂow cytometry and ﬂuorescent microscopy
and highlighted their prominent role in liver homeostasis and
displayed subtle differences from circulating monocytes. There
was some limited evidence that liver DCs are tolerogenic but nei-
ther liver dendritic cell subsets nor macrophages have been thor-
oughly characterized, using either multi-colour ﬂow cytometry or
multi-parameter ﬂuorescence microscopy. The lobular distribu-
tion of different subsets of liver MPS cells was also poorly
described, and the ability to distinguish between passenger leu-Journal of Hepatology 20
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that further research, using modern immunological techniques, is
now required to accurately characterize the cells of the MPS in
human liver.
 2014 European Association for the Study of the Liver. Published
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The immune system is precisely balanced between immune acti-
vation and tolerance. Within this system antigen presenting cells
(APCs) play a critical role in orchestrating the immune response
[1].
In the normal liver the immunological balance is weighted
towards a resting state of tolerance [2]. This immunological toler-
ance is seen in transplantation with a reduced rate of transplant
rejection, even acrossMHC-disparate barriers [3]. It is also evident
in infectious disease or cancer, with the liver readily harbouring
chronic diseases such as hepatitis C, and both primary and sec-
ondary malignancies [4]. Despite this functional tolerant state,
the liver can still under certain circumstances, such as transplant
rejection, induce a potent immune response [5].
Animal studies show heterogeneous populations of liver APCs
with varying functions that help to explain the liver’s tolerogenic
state and have identiﬁed these cells as potential therapeutic tar-
gets. A thorough understanding of the APCs in human liver will
be required to enable their therapeutic manipulation.
Although a number of cell types within the liver have the
potential to present antigens to T cells (broadly reviewed for
animal and human liver in [6] and [7]) – including stellate cells
(reviewed in [8]), endothelial cells (reviewed in [9]), and hepato-
cytes [7,10] – the intrahepatic cells of the mononuclear phago-
cyte system (MPS) play a major role in determining the nature
of the immune response [6,11]. This review therefore focused
on APCs within the MPS of the human liver, Table 1.
The MPS is composed of three major cells types – monocytes,
macrophages, and dendritic cells (DCs) – although as a result of
phenotypic and functional overlaps the precise boundaries, deﬁn-
ing these groups, are not certain. A current theory regarding the15 vol. 62 j 458–468
Table 1. Liver APC subsets, function and areas requiring further research.
Monocytes Molecularly defined
• CD14++CD16-
• CD14++CD16+
• DC-like phenotype - High 
DR, CD80+
• Macrophage-like 
phenotype - CD163+, 
CD68+
• CD16+CD14dim [21-23]
• CD14 “DC”-Postulated to 
be monocyte derived [98]
CD16+ monocytes (undefined as 
to whether they CD14++CD16+ or 
CD16+CD14dim) possess superior 
phagocytosis compared to blood 
monocytes and can efficiently activate 
CD4+ T cells [21-23]
Sinusoidal, 
throughout 
lobule [21-23]
• Functional assays 
of different 
CD14++CD16+
subsets
• Accurate distinction 
between monocyte, 
DC, and LM
• Identification of 
therapeutic targets
Liver macrophages • Pan CD68 expression
Moleculary defined
Heterogeneity present but no 
clear subset definition using 
molecular markers except the 
presence of macrophage-like 
monocytes (see above)
Morphologically defined
• “Thin”-extended cytoplasm 
[32]
• “Round”-larger cells with 
round cytoplasm [32]
• 5 subsets defined by 
varying endogenous 
peroxidase activity and 
levels of endoplasmic 
reticulum [86]
• Minimal functional experimental 
evidence on liver macrophages
• Liver Macrophages appear to 
be predominantly tolerogenic 
in nature, with a regulatory and 
scavenging role [41,57,69,89]
• Function inferred through 
observations of variable 
expression of antigen presenting 
molecules [72], lectins 
[33,49,55,69,92], Fc Receptors, 
complement receptors [70], low 
co-stimulatory marker expression 
[77] and inhibitory markers such 
as Z39Ig [89]
Perisinusoidal 
[78]
• Further detail around 
subset definition and 
function
• A variety of markers 
have been identified, 
but how this affects 
function is unknown, 
and how this changes 
according to subset 
is unknown
• Identification of 
therapeutic targets
Dendritic cells Moleculary defined
• BDCA1 (CD1c+) DC
• BDCA2 (CD303+) DC
• BDCA3 (CD141hi) DC
Also two subsets defined as 
having high lipid and low lipid 
content [101]
Tolerogenic in nature
• Lower expression of co-
stimulation markers compared to 
spleen [98]
• Produce IL-10 on LPS 
stimulation [98]
• Stimulate T-cells that are IL-10 
producing and hypo-responsive 
on re-stimulation [98]
• Produce higher numbers of 
FoxP3+ Treg cells on naïve T cell 
stimulation [98]
• Weak MLR response compared 
to blood [98]
Portal tract 
[103]
• Further subset 
distinction using 
transcription factors 
and markers 
expression
• Functional assays 
of all subsets, 
including CD8+ T 
cell stimulation, 
response to gut-flora
• Identification of 
therapeutic targets
Liver APCs can be divided into monocytes, macrophages, and dendritic cells. Monocytes are the most thoroughly investigated subset regarding accurate functional analysis
and have a different proportional composition of monocyte subsets compared to blood. Macrophage heterogeneity remains undetermined and very little functional data
exists for macrophages. Dendritic cells appear to represent the subsets found in blood but little functional data is available regarding these subsets.
JOURNAL OF HEPATOLOGYontogeny of the MPS, based on animal evidence, is summarized in
Fig. 1.
Compared to other cells in the body, those of the MPS appear
to be superior at sampling their environment through phagocyto-
sis, and presenting antigen to T cells, especially to CD4+ T cells via
MHC class II molecules (HLA-DP, -DQ, and -DR) [12]. APCs of the
MPS appear to have a commensurately increased expression of
antigen presentation and co-stimulatory molecules, and are
potent secretors of modulatory cytokines [12]. They are motile,Journal of Hepatology 201and in other tissues have been shown to express chemokine
receptors which facilitate their transit to draining lymph nodes,
prime naïve T cells and establish a systemic immune response
[13–15]. It is for these reasons that cells of MPS have become
attractive targets to manipulate for therapy, as well as monitor
for changes in disease states [16].
Interpreting experimental data regarding MPS cells in the
liver requires an appreciation of their diversity. In blood and
other tissues, monocytes, macrophages and DCs can be further5 vol. 62 j 458–468 459
Review
divided into subsets with different potential for antigen presenta-
tion, motility, and cytokine production, all of which can help
determine the nature of the immune system’s response [17]. A
particular complicating factor in the case of the liver is that circu-
lating monocytes also trafﬁc through the sinusoids, and distin-
guishing between in transit monocyte subsets and other MPS
subsets is an evolving science [17]. Indeed the body’s entire cir-
culation of blood passes through the liver numerous times a
day [18], so it is crucial to try and distinguish the role of MPS cells
that are resident in the liver from those that are passing through
it. In this review we were therefore careful to distinguish
between ﬁndings that may relate to monocyte subsets in transit
within the sinusoids rather than liver-resident MPS cells, espe-
cially those that are perisinusoidal, or reside in the portal tract.
Key Points 1
• Cells of the mononuclear phagocytic system (MPS) play 
a prominent role in antigen presentation to cells of the 
immune system locally and in draining lymph nodes
• Like other tissue, the human liver possesses all 
three major cells types of the MPS – monocytes, 
macrophages, and dendritic cells (DC). Liver monocytes 
and DC have a similar composition to blood but there is 
some evidence that they are more tolerogenic
• Liver macrophages have been broadly described as 
Kupffer cells, though they are clearly comprised of 
diverse subsets. Animal evidence indicates subsets 
of liver macrophages have distinct ontogeny and 
functions, but this concept has yet to be fully explored 
in humans
• New research is required to accurately define the 
subsets of MPS cells within normal human liver tissue 
and to adequately determine their function and their 
roles in liver homeostasis and pathology
• Better understanding of the liver MPS will enable the 
discovery of potential targets for immunotherapeutic 
intervention in liver disease and transplantationMethods
An electronic search was performed of the Medline and EMBASE databases from
1950 to July 2013 and 1980 to July 2013, respectively. Subject headings (MeSH)
and truncated word searches were used for the following terms: [antigen pres-
ent$, kupffer cell, macrophage, monocyte or dendritic cell] and [liver$ or hepat$].
Terms to incorporate the immunophenotype were based on methodology and
included [histology, phenotype, immunophenotype, immunohistochemistry, ﬂow
cytometry or electron microscopy]. Studies were excluded if (i) the liver was dis-
eased or transplanted, (ii) did not describe use of a normal human liver, or (iii)
were not original research (systematic review, narrative review, commentary or
editorial), Fig. 2. Articles were identiﬁed electronically using the above search
strategy and eligible abstracts were screened manually by the primary reviewer
(O. Strauss). Selected articles were retrieved and screened in depth for eligibility,
and reference lists were manually checked for other potentially papers. Human
studies focussing on diseased liver but also describing positive immunopheno-
typic ﬁndings of normal controls in liver tissue were included in the analysis.
Duplicate studies were excluded and only articles published in the English lan-
guage were included.460 Journal of Hepatology 201Results
Liver monocytes
Subsets and phenotype
Sinusoids of the liver contain circulating cells including mono-
cytes. While some of these cells transit through the liver and
return to the systemic circulation, others may adhere to the sinu-
soidal endothelium and ultimately differentiate into KCs [19].
Four papers described the immunophenotype of liver mono-
cytes [20–23]. All the subsets of monocytes found in the blood
are found in the liver.
Three major subclasses of monocytes are currently reported to
exist in the blood [24]. The ‘‘classical’’ CD14+CD16 subset, the
‘‘non-classical’’ CD14loCD16+ subset, and the ‘‘intermediate’’
(CD14hiCD16+) [17] subset that appears to be in a transitional
state between classical and non-classical monocytes [24]. In vivo
monocytes can probably also differentiate into ‘‘CD14+ DC’’ [25]
that are HLA-DRhiCD11c+ but lack other DC markers, with a tran-
scriptional proﬁle closest to in vitro cultured monocyte-derived
dendritic cells (MoDC). It is postulated that they are the in vivo
equivalent of a MoDC and in keeping with this they possess many
phenotypic and genomic characteristics of monocyte derived
macrophages [26].
In the liver compared to blood, there is a decreased proportion
of classical CD14hiCD16 monocytes (80% vs. 50%), and an
increased level of intermediate CD14hiCD16+ monocytes (9% vs.
27%), whereas the frequency of non-classical monocytes is
unchanged [22]. The increased proportion of intermediate mono-
cytes in the liver is thought to be due in part to the increased abil-
ity of CD16+ monocytes to transmigrate across the hepatic
endothelium as well as through an increase in local differentia-
tion from classical CD14hiCD16monocytes as a result of the high
levels of IL-10 and transforming growth factor beta. These inter-
mediate (CD14hiCD16+) monocytes in the liver exhibit features of
potent T cell stimulators, such as high HLA-DR, CD80, CD83, and
CD86 [22]. They also express CD163, often described as a macro-
phage cell-surface marker, though it is also rapidly upregulated
on the surface of activated monocytes.
As noted below, immunoﬂuorescence microscopy also
conﬁrmed that some CD14+, CD16+, and CD14+CD16+ cells
co-expressed CD68 – most commonly associated with macro-
phages. While the CD68 cells were probably monocytes in transit
through the sinusoids, the expression of CD68+ may indicate
monocytes differentiating into tissue macrophages within the
liver. Given that CD14 is also expressed by sinus-resident cells
of the MPS in human lymph nodes [27], it is also possible that
CD14 is expressed by at least some MPS cells that are resident in
the liver sinusoids, as well as monocytes in transit. The current lit-
erature is unable to distinguish between these possibilities.
The most thorough investigation of liver monocytes reported
only performed ﬂuorescence-activated cell sorting (FACS) on
CD16+ monocytes (comprising both intermediate and non-classi-
cal monocytes) and showed that these cells could efﬁciently pres-
ent antigen to autologous T cells [22]. This is in keeping with the
ﬁnding that intermediate monocytes expressed high HLA-DR,
CD80, CD83, and CD86. All three subsets of monocytes in the
normal liver express CCR2 [21–23], and this is supported by liver
tissue gene expression analysis [23]. As has been shown in stud-
ies in mice [19], this suggests that CCL2 (monocyte chemoattrac-
tant protein 1) will be a major mediator of monocyte recruitment5 vol. 62 j 458–468
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Fig. 1. Postulated ontogeny of liver antigen presenting subsets. Liver macrophages can broadly be deﬁned as monocyte derived macrophages or self-replicating yolk-sac
derived macrophages. The point at which a monocyte becomes a macrophage is not clearly deﬁned. Liver dendritic cells (DCs) also contain a population of monocyte
derived cells, these are important in inﬂammatory states. Liver DCs are also derived from immature blood dendritic cells that develop from a dendritic cell precursor. HSC,
haematopoietic stem cell; LMPP, lymphoid-primed multipotent progenitor; CMP, common myeloid progenitor; MDP, macrophage and DC progenitor; CDP, common
dendritic cell precursor; pDC, plasmacytoid dendritic cell.
JOURNAL OF HEPATOLOGYinto the liver in humans. Further to that, an in vitro model
assessed the recruitment of human peripheral blood CD16+
monocytes across human liver sinusoidal endothelium and high-
lighted the expression and importance of CX3CR1 in the transmi-
gration of this subset of monocytes [20], however this has yet to
be assessed on intrahepatic monocytes.
Kupffer cells (KCs)
Macrophages in the liver are generally described as Kupffer cells
[28]. The small amount of human data and growing amount of
mouse data, supporting heterogeneity of tissue macrophages in
general [29] and KCs in particular [30], highlight the historical
confusion about the accurate deﬁnition of these cells. In 1876
Karl von Kupffer described what he thought was the ‘‘phago-
some rich’’ cell of the reticuloendothelial system; in fact he
described liver stellate cells, with their large number of vitamin
A-containing globules. It was only in 1970, that Wisse et al. used
electron microscopy to clearly deﬁne the presence of peri-sinu-
soidal macrophage cells. Despite the misnomer, the term ‘‘Kupf-
fer cell’’, has become synonymous with that of ‘‘liver
macrophage’’ [28].
This review found sixty-seven papers that described the
immunophenotype of human liver macrophages [21–23,31–94].
Physical and phenotypic description
KCs have also been deﬁned by their peri-sinusoidal location in
the liver lobule [95], and a morphological appearance thatJournal of Hepatology 201demonstrates a lack of the extensive ﬁne cell membrane pro-
cesses, usually found on dendritic cells. Scanning electron
microscopy has demonstrated that KCs possess numerous lamel-
lipodia, and show pronounced membrane rufﬂing [66]. They are
described to classically lie tightly attached to the sinusoidal lumi-
nal surface [78]. Data are conﬂicting as to changes of KC density
within the liver lobule; KCs have been described as being more
densely populated in peri-central regions [36], but were also
described as being diffusely pan-lobular, involving both the por-
tal tracts and regions around the central vein [38].
Only a few cellular markers have been described in humans
that are consistently expressed by KCs. CD68, a lysosome associ-
ated trans-membrane glycoprotein, involved in the metabolism
of the low-density lipoprotein, is the most consistent reported
marker for determining macrophage populations throughout
the body and has been used throughout the literature to deﬁne
macrophages within the liver. Subsequently the majority of
papers (n = 37) used immunohistochemistry or ﬂuorescence
microscopy to describe the presence or absence of further cellular
components (such as cell surface markers, or tissue distribution)
on cells that also stain positive for CD68. Hence, a good working
deﬁnition for a Kupffer cell in the literature to date is a peri-sinu-
soidal cell expressing CD68.
Heterogeneity
A number of papers report heterogeneity of KCs but to date there
is no comprehensive deﬁnition of KC subsets. Morphological5 vol. 62 j 458–468 461
Potential relevant articles screened
(N = 5200)
Articles retained for detailed evaluation
(N = 200)
Articles included in review ( N = 76)
Excluded articles (N = 5000)
• Animal study (N = 752)
• Cancer (N = 898)
• Infection (N = 833)
• Not liver-related (N = 467)
• Disease otherwise (N = 762)
• Transplant related (N = 238)
• Not describing APC phenotype (N = 638)
• Review (N = 412)
Excluded articles (N = 124)
• Paper was in fact a review (N = 5)
• Animal study (N = 6)
• No phenotypic description (N = 17)
• No positive findings ( N = 32)
• Duplicate (N = 64)
Fig. 2. Quorum. Quorum diagram of results.
Reviewdifferences have been noted, such as macrophage populations
with varying cell shapes in the portal compared to the central
venous regions of the liver lobule [95], or two different popula-
tions of KCs being described as either ‘‘round’’ or thin’’ [32]. In
1995, Ueda et al. [86] described KC functional heterogeneity
based on endogenous peroxidase activity that divided the cells
into monocytes and four types of macrophages that showed a
zonal distribution. These ﬁndings suggest that KCs are a collec-
tion of cells with varying phenotypes throughout different parts
of the healthy liver, which is a concept that has been further sup-
ported by work in chronically hepatitis C virus infected livers
[16].
The heterogeneous co-expression of other phenotypic mark-
ers by CD68+ cells supports KC heterogeneity. As noted above,
some CD68+ cells co-express CD14, CD16, and CD163 [22] though
it is not clear whether all these cells are resident macrophages,
since activated monocytes can express all these molecules. Some
KCs express Mac387, a marker for inﬁltrating macrophages as
opposed to resident macrophages [42]. Similarly, CD68+ liver
cells variably co-express a large range of APC markers, including
lectins (CD209 [23], and CD299 or LSECtin [40]), complement
receptors (predominantly CR1, CR3, and CR4 [70] and C5a
(CD88) receptor [34]), Fc receptors (such as CD16, CD32, and
CD64 [56]), and scavenger receptors (such as CD206 [40],
CD163, and CD169 [69]). How the variable expression of all these
markers in KCs relates to different locations within the liver lob-
ule, and different cellular lineages, remains unclear.
Intriguingly, some CD68+ KCs in healthy liver express the pro-
liferative marker, Ki67 [21], suggesting they are self-renewing
in situ, rather than terminally differentiated cells derived from
blood cells. In this context it is important to note recent evidence
inmice (discussed below) for tissuemacrophages that derive from
the yolk sac and foetal liver rather than the bone marrow [29].462 Journal of Hepatology 201There is very little direct experimental evidence of the func-
tion of human KCs, so their roles are largely inferred from histol-
ogy, electron microscopy, immunohistochemistry, and evidence
from murine models.
Macrophages are classically not considered as potent as DCs at
stimulating a T cell response, or as capable of travelling to drain
secondary lymphoid tissue to instigate a systemic response [29].
However, KCs appear to be heavily involved in both the innate
and the acquired immune responses within the liver. KCs express
MHC class II, and express varying levels of co-stimulation mark-
ers (such as CD40, CD80, and CD86 [77]), as well as the inhibitory
markers such as Z39Ig [89]. In the steady state they act as senti-
nel scavenging cells to process antigen from the gut. KCs readily
phagocytose latex beads [96] and therefore play a major scaveng-
ing role in conjunction with the liver sinusoidal endothelial cells
(LSECs) [33]. The migratory potential of KCs is still uncertain and
although monocytes clearly express CCR2 and CX3CR1, expres-
sion of chemokine receptors in CD68+ cells is yet to be thoroughly
explored [22].
Electron microscopy has shown KCs in direct contact with pit
cells (liver NK cells), and liver stellate cells (the major collagen
producing cell in the liver [78]). It is postulated that through this
interaction they are key in instigating ﬁbrosis following inﬂam-
mation [93]. CD68+ KCs also co-express prokineticin 2/Bv8, a
molecule strongly implicated in angiogenesis [43].
Liver dendritic cells
Ten papers describe the immunophenotype of liver dendritic
cells (DC) in human liver [20,51,95,97–103].
Although the boundaries between macrophages and DCs have
blurred in recent years, the major human DC subsets express
well-deﬁned cell surface markers that allow for their identiﬁca-
tion, using ﬂow cytometry and multi-colour immunoﬂuorescence5 vol. 62 j 458–468
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microscopy. Much of this work has been carried out using cellular
markers common to DCs in blood and other non-hepatic tissue.
DCs in human blood are HLA-DRhi cells that comprise 3 major
non-monocytic subsets: plasmacytoid DCs (pDCs) expressing
CD303 (BDCA2) and lacking CD11c; and two myeloid CD11c+
subsets – CD1c+ DCs expressing CD1c (BDCA1); and CLEC9A+
DCs expressing CLEC9A and high levels of CD141 (BDCA3) [25].
Peripheral and lymphoid tissues also have at least two myeloid
CD11c+ migratory DC subsets (e.g. Langerhans cells) that express
molecules such as CD207 and CD1a [27,104,105]. CD1c+ DC can
secrete IL-10 in response to incubation with whole E. coli and
the TLR-4 agonist lipopolysaccharide [106] and are therefore
thought to have tolerogenic potential.
It is apparent that all three major classes of blood DCs are
present in the liver, in addition to CD16+ monocytes [98], with
CD1c+ DCs being the most prevalent subset [98]. The hepatic
DC populations express similar markers to blood DCs, and when
compared to skin and spleen DCs, liver DCs have an immature
phenotype, with a relatively low expression of co-stimulatory
molecules (CD40, CD80, and CD86), as well as maturation mark-
ers like CD83 [98,99].
Compared to blood, hepatic DCs were less efﬁcient at antigen
uptake, processing and presentation, including allo-stimulatory
capacity, and upon TLR4 stimulation they secreted substantial
amounts of IL-10, a cytokine associated with a tolerogenic pheno-
type [107]. Kwekkeboom et al. [108] found that compared to
inguinal lymph node DCs, hepatic DCs were less capable of stim-
ulating T cells, despite higher expression of HLA-DR, CD80, and
CD86. Bamboat et al. found increased production of Foxp3+ Treg
cells and IL-4 producing T cells (associated with the humoral
immune response [109]) that were difﬁcult to re-activate if ini-
tially activated by hepatic DCs in comparison to blood-derived
DCs. Interestingly, liver DCs were also found to have a signiﬁ-
cantly decreased secretion of IL-12p70, which has been viewed
as a pro-inﬂammatory cytokine [110].
Goddard et al. [99] used overnight migration to extract DCs
from the liver. They found high HLA-DR, CD86, and CD11b prior
to culture. They also found that these hepatic DCs produced lar-
ger amounts of IL-4 and IL-10 and lower levels of IL-12p70 com-
pared to DCs from the spleen and skin. They report that the DCs
extracted, using overnight migration, expressed low levels of
CCR5 and were positive for the chemokine receptor CXCR4 and
CCR7. Very little other work on intrahepatic liver DC chemokine
receptors has been published.
In 2012 Haniffa et al. described the presence of CD141hi DCs in
the liver, using multi-colour ﬂow cytometry, and also conﬁrmed
the presence of CD14+ APCs and CD1c+ DCs. CD141hi DCs in other
human tissues also express the deﬁnitive marker CLEC9A, and
some reports indicate that these cells have some of the character-
istics of murine CD8+ or CD103+ DCs [111], especially the ability
to cross-present antigen to CD8+ T cells. However, no functional
data from normal intrahepatic CD141hi DCs have yet been pub-
lished [112].
Further to studies of liver tissue from biopsy samples, liver
perfusates from liver transplant procedures have described
CD141 expressing DCs that appear to be of a more pro-inﬂamma-
tory phenotype than CD14+ and CD1c+ MPS in the liver [102].
However, it is apparent that CD141 is much more widely
expressed in liver cells than in blood, where it is largely restricted
to CLEC9A+ DC [111]. Hence, CLEC9A+ DCs may only be a subset of
the CD141+ cells, derived from human liver, so results from sort-Journal of Hepatology 201ing on CD141 alone need to be interpreted with some caution
[113].
While the majority of research on liver DCs has been to assess
phenotype using ﬂow cytometry, there is a small amount of his-
tological work localising DCs, this has used light microscopy and
immunohistochemistry. Myeloid DCs are predominantly located
in the portal tract and periportal zones, with particular density
around the bile ducts while pDC are found scattered throughout
the liver lobule [114].Discussion
Although similar, monocytes in the liver are different from the blood
As we noted, three major subsets of blood monocytes are consid-
ered to be present in liver, and it appears that liver monocytes are
richer in CD16 expression than monocytes in the blood. CD16
monocytes probably derive from CD14 monocytes [115] and
the increased number of CD16 monocytes may relate to the acti-
vation of classical monocytes in the liver. Clearly some cells bear-
ing monocyte markers also express markers more commonly
associated with KCs such as CD68 and CD163 [22]. Monocytes
are therefore likely to be involved in transient inﬂammatory
responses in the liver, but may also be precursor cells to some
DC and KC populations, even in normal liver.
The literature does not deﬁne a organ resident or passenger MPS
The liver is a unique organ as it is highly vascular, blood ﬁltering,
and maintains a tissue resident population of the MPS. We cur-
rently lack markers that deﬁne cells that are transiently passing
through the organ from those that are tissue resident. The fact
that cells, bearing monocytic markers, can upregulate molecules
more commonly associated with macrophages, such as CD68 and
CD163, suggests that MPS precursors may alter their phenotype
substantially as they trafﬁc through the liver, and/or seed popu-
lations of KCs and DCs within the liver. Monocyte markers them-
selves are problematic: CD14 is also expressed by sinus-resident
APCs in other human lymphoid organs [27], and also by endothe-
lial cells [22], so it may not be speciﬁc for monocytes in the
human liver; and CD14lo ‘‘non-classical’’ monocytes, transiting
through the sinusoids, may be difﬁcult to distinguish from resi-
dent KC populations.
Analysis of c-Myb expression may be informative in this con-
text. It was recently reported that the majority of tissue macro-
phages that persist into adulthood in mice appear to be
negative for the transcription factor c-Myb, which is present on
cells derived from haematopoietic stem cells [116]. A series of
lineage tracking studies in mice have shown that the majority
of tissue macrophages are not replenished from bone-marrow
derived monocytes, but are self-replicating macrophages that
seed the tissue from the yolk-sac and the foetal liver during
embryogenesis [117]. Small numbers of macrophage populations
are derived from monocytes under homeostatic conditions in the
adult liver, with further mobilization of these cells only under
inﬂammatory conditions [118]. Hence, it should now be feasible
to identify markers, capable of unequivocally distinguishing
between blood-derived MPS and those resident KCs that do not
originate from a bone marrow precursor. Further to that, as in5 vol. 62 j 458–468 463
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other tissue [26], analysis of transcription factors may improve
this.
Several DC subsets are present in the liver
Liver DC subsets are more thoroughly described than liver mac-
rophages, due to the more recent application of multi-parameter
ﬂow cytometry, detecting deﬁnitive cell surface markers.
The current evidence points to the liver containing similar DC
populations as other tissue. All the major subsets found blood,
including pDCs, CD1c+ DCs and CLEC9A+ DCs appear to be pres-
ent. Unfortunately, functional data on these subsets are limited,
as is a detailed expression of their phenotype (such as a complete
description of the pathogen recognition receptors, CCRs, and lec-
tins). The small amount of published data suggests that they are
less mature than DCs found in blood and spleen, poorer at elicit-
ing an antigen speciﬁc T cell response or MLR, and are associated
with an increased production of IL-4 and IL-10 [98]. Of particular
interest is the relative immunogenicity of CD141+ cells in both
normal and diseased liver. Considering the increased expression
of CD141 in tissue DC populations [119], it will be important to
determine whether this is due to CD141hiCLEC9A+ cells or any
other liver cell that happen to express CD141.
The tolerogenic environment of the liver and the MPS
Although cells of the MPS are implicated in producing the toler-
ogenic environment of the liver, there remain large areas of MPS
characterisation to be explored. However the limited data avail-
able from liver DCs suggest substantive differences in their ability
to perform some functions, such as phagocytosis, migration, T cell
stimulation, cross-presentation, and speciﬁc cytokine secretion.
Tolerance in the liver appears to be due to many factors,
including the nature of T cells, the effect of other non-parenchy-
mal cells, and large amounts of TGF-beta [120]. Production of
IL-10 in response to bacterial cell wall components represents a
prominent tolerogenic mechanism that appears to occur in all
three groups of MPS cells in the liver. Considering the large
amounts of bacterial cell wall products that enter the liver
through the portal vein in the normal liver [121], this mechanism
may be central to the liver’s tolerant state. Studies of liver perfu-
sates [122] have supported these ﬁndings and it appears that the
loss of this mechanism in cirrhosis may be due to a modiﬁcation
of the MPS [123].
An area notably lacking data concerns the physiological
response of the liver MPS to the presence of whole bacteria
[121]. Translocation of bacteria and bacterial fragments from
the gut is a common occurrence [11], and the responses they
induce in different liver MPS subsets warrant further investiga-
tion as they presumably are part of the physiological role of some
liver MPS subsets in vivo. In human blood, whole E. coli appears to
promote a further induction of IL-10 expression by CD1c+ DCs
[106] that is independent of TLR ligation; it is yet to be deter-
mined if this occurs in the liver, but may also be a further contrib-
uting factor in promoting hyporesponsiveness.
The liver DCs appear to have a relatively immature phenotype
with a lower expression of co-stimulatory markers [98]. This,
coupled with their inferior abilities of antigen uptake, processing
and presentation, may be contributing factors to their decreased
ability to simulate T cells [98,99]. When T cells are primed by
liver DCs they are then more difﬁcult to re-activate compared464 Journal of Hepatology 201to blood DCs (this T cell hyporesponsiveness appears to be par-
tially regulated through an IL-10 dependant mechanism), and
are more likely to be Foxp3+ regulatory T cells [98]. These are
all factors that may contribute to a tolerogenic environment in
the liver.
Kupffer cells appear to be heterogeneous
In general, KCs harbour many of the characteristics of other tissue
macrophages. They readily phagocytose latex beads [96] and
express a variety of macrophage related scavenger receptor mol-
ecules [40,69]. However, there is clearly variability in the expres-
sion of these markers and other molecules amongst KCs and light
[32] and electron [86] microscopy ﬁndings have identiﬁed that
KCs are composed of differing subsets of cells, which are distrib-
uted through different zones of the liver lobule. These ﬁndings
indicate that KCs appear to be heterogeneous, but exploration
of KC subset composition and function is lacking.
Through their expression of molecules involved in the presen-
tation of antigen to T cells (MHC class II, T cell co-stimulatory
molecules) it seems likely that at least some KCs are involved
in presenting antigen to liver-resident T cells but their migratory
potential and their capacity to trafﬁc antigen to lymph nodes
remain uncertain.
Macrophages are particularly difﬁcult cells to isolate from
human liver, due to the loss of large numbers of cells during iso-
lation and lack of consistent cell-membrane markers that can be
used in cell sorting. CD68 has a variable expression on the cell
surface [124], and little else beyond CD14, CD16, and CD163
has been considered, despite the obvious overlap with transiting
monocytes [22,125].
There is therefore a need to deﬁne and accurately sort KC sub-
sets, in order to enable functional assays for studies in both
healthy liver and disease. Multicolour ﬂuorescence microscopy
and ﬂow cytometry may provide sufﬁcient details to accurately
and comprehensively assess a molecular phenotype for KCs (as
has been the case with characterizing other cell subsets [126]).
As our understanding of the complexity of macrophages
increases, the limits of general terms, such as ‘‘Kupffer cell’’
[127], may make it timely to review and revise our terminology.
Liver microanatomy
Ultimately, understanding MPS function in the liver will require
an appreciation of histological differences in the distribution of
these different subsets throughout the different areas of the liver
and an improved understanding of their role and interaction with
sinusoidal endothelia, stellate cells and other leukocytes. Despite
data indicating other cell types, such as hepatocytes [128] and
LSECs [129,130] that are different in different zones of the liver,
little data exist beyond gross morphological observations for
zonal distributions of different MPS populations, especially KCs.
Although it is apparent that KCs are scattered throughout the
liver lobule, without sophisticated techniques to determine sub-
sets, based on molecular marker expression, using more than one
marker (such as CD68) it is impossible to ascertain any accurate
intralobular differences in subset distributions, or examine how
MPS function changes with location. It would be reasonable for
the composition and function of perisinusoidal KCs to also change
across these zones as observed with hepatocytes [128] and LSECs
[129,130]. KCs are closely associated with the sinusoidal5 vol. 62 j 458–468
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endothelia; and are likely to be able to interact extensively with
the slow moving plasma and blood cells as they transit [11].
In contrast, the portal tract is where the majority of the liver’s
dendritic cells reside [6], and it becomes very heavily populated
with leukocytes during liver inﬂammation [131]. The portal tract
also houses the lymphatic endothelium, and is hence the conduit
through which the MPS will travel to draining lymph nodes. As a
result of these features it is thought to be the area of the liver lob-
ule where the majority of antigen presentation to T cells occurs. A
thorough understanding of the relationship of each MPS subset to
the micro-anatomical structure of the liver will therefore help to
inform knowledge of their function.Clinical signiﬁcance
In the case of transplantation, despite showing superior graft
acceptance in comparison to other transplanted organs, graft
rejection is still a major problem in the liver transplant setting
with rejection rates as high as 20–40% [132]. The focus of the cur-
rent therapy is primarily to reduce the presence of a pro-inﬂam-
matory state at the time of transplantation through the use of
calcineurin inhibitors, such as cyclosporin or tacrolimus in combi-
nation with cytolytic agents, such as mycophenolate or azathio-
prine [3]. These drugs are associated with signiﬁcant side
effects, directly through renal and cardiac toxicity but also
through the indirect effects of inducing a broadly dysregulated
immunological state, leading to higher rates of cancer, infection,
and de novo autoimmune disease [133]. The study of MPS in the
liver will therefore improve our understanding of the liver’s toler-
ogenic state and the nature of the biological processes, involved in
the loss of this normal state. Understanding which subsets are
most tolerogenic or immunogenic may identify targets for up-
or downregulation, depending on the desired tissue response.
Further to this, appreciating which subsets are most capable
of antigen presentation and T cell stimulation allows for the
opportunity to improve the efﬁcacy of immunotherapy directed
towards cancer and infectious diseases. Primary liver cancers,
such as hepatocellular carcinoma (HCC), and metastasis (for
example from colon cancer), have a high mortality rate and con-
tinue to pose huge burdens on the medical community [134].
HCC in particular reﬂects the consequences of long-term liver
inﬂammation through insidious disease and infection, such as
hepatitis C and hepatitis B, both of which place a huge burden
on global health [135].Conclusion
Currently strategies to manipulate the liver MPS are impaired by
a lack of appreciation of the populations of monocytes, macro-
phages and DCs present in human liver, and their functional attri-
butes. Modern techniques, already being used to describe MPS
populations in other organs, should now be implemented to
improve the understanding of the liver MPS. An improved and
more accurate understanding of these cells will be vital for the
accurate description of cell function, and elucidation of appropri-
ate targets for therapy. This will cover a range of applications
from enhancing immunity to cancer or infectious agents, to
inducing and maintaining tolerance, such as in liver transplanta-
tion and autoimmune disease.Journal of Hepatology 201Financial support
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